Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
The company announces that it plans to file a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (U.S. FDA) for an NP-120 (Ifenprodil) Phase 2 chronic cough study. Read more
PsyBio Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
The company reported its unaudited financial results for the three-month period ended June 30, 2021 and provided shareholders with a corporate update. Read more
Enveric Biosciences Announces Closing of MagicMed Industries Acquisition
Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress. Read more
Company Broadens Scientific Expertise with Addition of Mental Health Expert in Setting Up and Managing Interventional Psychiatric Clinics. Read more
AdvisorShares’ New Psychedelic ETF Launches on the NYSE
The first actively managed fund, the “PSIL” ETF is another step forward for the psychedelic medicine industry. Read more